Medical Technology

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 3 years ago

Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases

@xconomy.com 3 years ago

Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact

@xconomy.com 4 years ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Frequency Plans IPO for Hearing Loss Drug & More Regenerative Meds

@xconomy.com 4 years ago

As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing